T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases. Founded in 2022, the company is based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine. Professor Allan Bradley has previously founded several companies including Kymab, a company developing fully human monoclonal antibodies […]

Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal and plant genomes, Empyrean is working to enhance and modulate neuroactive compounds produced by these kingdoms. Launched in 2022, the company’s platform is being used […]

EnPlusOne Biosciences aims to bring a versatile, sustainable, and scalable RNA synthesis technology to market to unlock development of new RNA drugs, vaccines, and gene-editing therapies. The company’s advanced-stage technology has more than six years of development at the Wyss Institute at Harvard University, and is co-founded by Dr. George Church of Harvard Medical School. […]